Lipids in Cancer - Advanced nanospectroscopic profiling and assessment of non-conventional drugs for cancer therapy

癌症中的脂质 - 先进的纳米光谱分析和癌症治疗非常规药物的评估

• 批准号: 2104299
• 金额: --
• 依托单位: University of Strathclyde
• 依托单位国家: 英国
• 项目类别: Studentship
• 财政年份: 2018
• 资助国家: 英国
• 起止时间: 2018 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=studentship-2104299
• 关键词: Lipids; Cancer; Advanced; nanospectroscopic; profiling

This project aims to investigate the use of Raman scattering and some of its variations (surface enhanced (SERS), coherent anti-Stokes (CARS) and stimulated (SRS)) to assess the profiling of lipids in cancer cells and tissue prior to and following treatment with conventional anticancer drugs and particularly new alternative drugs that have shown promise as anticancer agents. Raman scattering is a powerful vibrational technique that can provide label free images of cells and tissue based on specific molecular vibrations. To image large areas using Raman scattering can take considerable time, however, the development of coherent anti-Stokes Raman scattering (CARS) and stimulated Raman scattering (SRS) has enabled image acquisition to take place very rapidly through the use of a two photon non-linear process to monitor a single vibrational wavelength, which allows the collection of images in a matter of seconds from large areas of tissue. We can tune into lipid vibrations and produce highly visual images of tissue. Typically Raman scattering is a weak process, however, the insensitivity of Raman scattering can be improved through the use of metal nanoparticles, which can enhance Raman scattering but also be used to provide localised and more efficacious drug response when drugs are added to their surface.Changes in lipid biosynthesis is a fundamental aspect of cancerous growth, with de novo lipid synthesis markedly upregulated in cancer tumours. To date the technologies available for analysing lipids are either destructive e.g. mass spectrometry or require the use of bulky extrinsic labels that can interfere significantly with innate biological processes e.g. fluorescence. In this project we propose to understand the altered lipid metabolism in cancer, and the role of drugs that target lipids and lipid synthesis as potential candidates for improved and alternative cancer treatment. More specifically we are interested in understanding more about the cholesterol synthesis pathway and following this in real time using live cells and tissue. This is well beyond the current state of the art possible by any other technology. In particular, we are interested in using statins, which are conventionally used to treat cardiovascular disease, as agents to improve understanding of response to castration in prostate cancer patients. In a project funded by the EPSRC (EP/L014165/1), we are investigating the role of statins attached to metallic nanoparticles as improved agents for treatment of heart disease. This studentship will work in partnership with Prof Hiroshi Matsui at CUNY who is an expert in drug delivery to develop a way of following the effect of different drug/nanoparticle formulations on the progression of cancer using the methodology detailed in this proposal.

该项目旨在研究使用拉曼散射及其一些变体（表面增强（Sers），相干反斯托克斯（汽车）和受激（SRS））来评估传统抗癌药物治疗前后癌细胞和组织中脂质的分布，特别是新的替代药物，已显示出作为抗癌药物的前景。拉曼散射是一种强大的振动技术，可以提供基于特定分子振动的细胞和组织的无标记图像。使用拉曼散射对大面积进行成像可能花费相当长的时间，然而，相干反斯托克斯拉曼散射（汽车）和受激拉曼散射（SRS）的发展已经使得能够通过使用双光子非线性过程来监测单个振动波长而非常快速地进行图像获取，这允许在几秒钟内从大面积的组织收集图像。我们可以调谐到脂质振动，并产生高度可视化的组织图像。通常拉曼散射是一个弱的过程，然而，拉曼散射的不敏感性可以通过使用金属纳米颗粒来改善，金属纳米颗粒可以增强拉曼散射，但也可以用于提供局部的和更有效的药物反应时，药物被添加到其表面。脂质生物合成的变化是癌生长的一个基本方面，与从头脂质合成显着上调在癌症肿瘤。迄今为止，可用于分析脂质的技术要么是破坏性的，例如质谱法，要么需要使用大量的外来标记，这些标记可以显着干扰先天生物过程，例如荧光。在这个项目中，我们建议了解癌症中脂质代谢的改变，以及靶向脂质和脂质合成的药物作为改善和替代癌症治疗的潜在候选药物的作用。更具体地说，我们有兴趣了解更多关于胆固醇合成途径，并遵循这在真实的时间使用活细胞和组织。这远远超出了任何其他技术所能达到的现有技术水平。特别是，我们感兴趣的是使用他汀类药物，这是传统上用于治疗心血管疾病，作为代理，以提高对前列腺癌患者去势反应的理解。在EPSRC（EP/L014165/1）资助的一个项目中，我们正在研究附着在金属纳米颗粒上的他汀类药物作为治疗心脏病的改进药物的作用。该奖学金将与纽约市立大学的Hiroshi Matsui教授合作，他是药物输送方面的专家，使用本提案中详细介绍的方法，开发一种跟踪不同药物/纳米颗粒制剂对癌症进展影响的方法。